Diabetes

Results at ASHP 2019 suggest potential for administration errors without proper guidance.

Results from a poster at ASHP 2019.

Patients with type 2 diabetes should keep taking their medication.

Pharmacist-led initiatives, such as medication therapy management, for chronic diseases can significantly improve patient outcomes.

Great patient care and new business opportunities don’t have to be mutually exclusive.

Previously approved for IV infusion.

Reduces risk for heart failure and cardiovascular disease hospitalizations.

Tips for identifying patients with diabetes who need more direction and help.

Noteworthy diabetes management products and updates making waves this year.

New CGM eliminates fingersticks, introduces new data presentation.

Now approved for risk reductions in patients with type 2 diabetes mellitus.

Now approved in 7mg and 14 mg tablets.

Cost, education, self-monitoring, and more. 

First non-insulin drug for pediatric use approved in nearly 20 years.

Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.

Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor.

How pipeline promises-and disappointments-are impacting patients with diabetes.

New drug combines dapagliflozin, saxagliptin, and metformin.

Results from a recent ELLIPSE trial indicate superiority in reducing blood sugar when compared to the placebo.

Increase adherence by matching technology to each patient's unique needs.

Consumers are using test strips that might lead to inaccurate results. 

Eli Lilly creates generic Humalog priced 50% lower 

Rounding up the news you need to know to start the new year.

GPS-based dietary prompts, continuous glucose monitors among the devices poised to revolutionize diabetes treatment and patient management. 

Drug Topics spoke to several community pharmacists  about their diabetes education programs and how they can be a revenue stream. Here’s their advice for other pharmacists.